Alk Rearrangements | List of Frontiers open access articles

Case Report

Published on 29 May 2025

Case Report: ALK-rearranged mesenchymal neoplasms with S100 and CD34 co-expression: additional cases with distinct characteristics

in Skin Cancer

Qi Ouyang
Xiaohong Guo
Rongjun Mao
Zhixing Cao

Frontiers in Oncology

doi 10.3389/fonc.2025.1516491

2,044 views

Original Research

Published on 07 Jun 2022

Targeting ALK in Neuroendocrine Tumors of the Lung

in Thoracic Oncology

Dilara Akhoundova
Martina Haberecker
Ralph Fritsch
Sylvia Höller
Michael K. Kiessling
Markus Rechsteiner
Jan H. Rüschoff
Alessandra Curioni-Fontecedro

Frontiers in Oncology

doi 10.3389/fonc.2022.911294

6,061 views
21 citations

Review

Published on 06 Apr 2022

Targeting ALK Rearrangements in NSCLC: Current State of the Art

in Thoracic Oncology

Ling Peng
Liping Zhu
Yilan Sun
Justin Stebbing
Giovanni Selvaggi
Yongchang Zhang
Zhentao Yu

Frontiers in Oncology

doi 10.3389/fonc.2022.863461

25,561 views
72 citations

Case Report

Published on 23 Nov 2022

Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report

in Pharmacology of Anti-Cancer Drugs

Jiuzhou Zhao
Xiang Li
Ruizhe Fan
Yaping Qin
Zhizhong Wang
Bo Wang
Shaomei Li
Jianfeng Fan
Xinxin Wu
Hongxia Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1060460

2,978 views
5 citations

Mini Review

Published on 25 Nov 2014

Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC

in Thoracic Oncology

Alona Zer
Natasha Leighl

Frontiers in Oncology

doi 10.3389/fonc.2014.00329

10,037 views
35 citations

Mini Review

Published on 20 Mar 2017

Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer

in Thoracic Oncology

Barbara Melosky

Frontiers in Oncology

doi 10.3389/fonc.2017.00038

20,901 views
22 citations

Systematic Review

Published on 29 Apr 2021

Driver Genes Associated With the Incidence of Venous Thromboembolism in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

in Thoracic Oncology

Xiaohan Qian
Mengjiao Fu
Jing Zheng
Jianya Zhou
Jianying Zhou

Frontiers in Oncology

doi 10.3389/fonc.2021.680191

5,790 views
23 citations

Case Report

Accepted on 23 Feb 2026

Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor

in Cancer Molecular Targets and Therapeutics

JESUS GUSTAVO YARINGAÑO CERNA
Jorge Hernando
Alejandro García-Álvarez
Carmela Iglesias-Felip
Carles Zafón
Ana Vivancos
María Roca-Herrera
Sergio Pérez-Fernández
Sandra Martínez-Badal
Belén Elguero

Frontiers in Oncology

Case Report

Published on 18 Apr 2024

Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report

in Thoracic Oncology

Dan Li
Yue Zhu
Jincheng Song
Dafu Yang
Saiqiong Cui
Xin Liu
Le Wang
Jiangyan Zhang
Evenki Pan
Zhaoxia Dai

Frontiers in Oncology

doi 10.3389/fonc.2024.1339511

2,729 views
1 citation

Case Report

Published on 04 Mar 2022

SDK1-ALK Fusion in a Lung Adenocarcinoma Patient With Excellent Response to ALK Inhibitor Treatment: A Case Report

in Pharmacology of Anti-Cancer Drugs

Lin Ma
Junjuan Xiao
Yaping Guan
Dongfang Wu
Tiantian Gu
Jun Wang

Frontiers in Oncology

doi 10.3389/fonc.2022.860060

2,881 views
3 citations

Original Research

Published on 30 Jul 2025

Genetic alterations affect immune contexture of non-small cell lung cancer: Ukrainian study

in Pathology

Denys Kozakov
Nazarii Kobyliak
Sofiia Livshun
Oleksii Seleznov
Olena Koshyk
Alina Matvieieva
Yaroslav Shparyk
Oleksii Kolesnik
Yuliia Moskalenko
Oleksandr Vynnychenko

Frontiers in Medicine

doi 10.3389/fmed.2025.1558016

2,947 views
1 citation

Case Report

Published on 13 Dec 2024

Coexistence of a novel SV2B-ALK, EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review

in Pharmacology of Anti-Cancer Drugs

Huang Chen
Menglan Zhang
Liyan Bai
Yun Niu
Xiaowei Wang
Ruiying Jiang
Ye Wang
Qianqian Feng
Bei Wang
Tingli Dai

Frontiers in Oncology

doi 10.3389/fonc.2024.1453259

2,263 views
4 citations

Case Report

Published on 11 Aug 2025

Case Report: Locally advanced lung adenocarcinoma with a novel MIR217HG-ALK rearrangement responding to neoadjuvant alectinib

in Pharmacology of Anti-Cancer Drugs

Yinyin Xue
Wen Li
Kaili Huang
Qinghua Zhou
Qiang Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1602654

1,913 views

Original Research

Published on 20 Oct 2023

Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer

in Thoracic Oncology

Sergi Clavé
Jennifer B. Jackson
Marta Salido
Jacob Kames
Kelly M. R. Gerding
Ellen L. Verner
Eric F. Kong
Elizabeth Weingartner
Joan Gibert
Max Hardy-Werbin

Frontiers in Oncology

doi 10.3389/fonc.2023.1225646

5,430 views
4 citations

Case Report

Published on 21 Jan 2026

Case Report: IGFBP5-ALK fusion-positive case of high-grade endometrial stromal sarcoma with response to ALK-targeted therapy

in Gynecological Oncology

Weiwei Zhang
Jinkun Wu
Shujie Song
Yu Cheng

Frontiers in Oncology

doi 10.3389/fonc.2025.1720854

580 views

Original Research

Published on 01 May 2025

Radiomic features and tumor immune microenvironment associated with anaplastic lymphoma kinase-rearranged lung adenocarcinoma and their prognostic value

in Cancer Genetics and Oncogenomics

Ying Han
Wenya Feng
Huaxin Li
Hua Wang
Zhaoxiang Ye

Frontiers in Genetics

doi 10.3389/fgene.2025.1581937

2,407 views
1 citation

Articles

Case Report: ALK-rearranged mesenchymal neoplasms with S100 and CD34 co-expression: additional cases with distinct characteristics

Targeting ALK in Neuroendocrine Tumors of the Lung

Targeting ALK Rearrangements in NSCLC: Current State of the Art

Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report

Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC

Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer

Driver Genes Associated With the Incidence of Venous Thromboembolism in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor

Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report

SDK1-ALK Fusion in a Lung Adenocarcinoma Patient With Excellent Response to ALK Inhibitor Treatment: A Case Report

Genetic alterations affect immune contexture of non-small cell lung cancer: Ukrainian study

Coexistence of a novel SV2B-ALK, EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review

Case Report: Locally advanced lung adenocarcinoma with a novel MIR217HG-ALK rearrangement responding to neoadjuvant alectinib

Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer

Case Report: IGFBP5-ALK fusion-positive case of high-grade endometrial stromal sarcoma with response to ALK-targeted therapy

Radiomic features and tumor immune microenvironment associated with anaplastic lymphoma kinase-rearranged lung adenocarcinoma and their prognostic value